009420 — Hanall Biopharma Co Share Price
0.000.00%
Last trade - 00:00- KR₩2tn
- KR₩2tn
- KR₩135bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 104.11 | ||
| PEG Ratio (f) | 1.75 | ||
| EPS Growth (f) | 145.94% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.77 | ||
| Price to Tang. Book | 10.63 | ||
| Price to Free Cashflow | 79.84 | ||
| Price to Sales | 12.1 | ||
| EV to EBITDA | 290.51 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.08% | ||
| Return on Equity | 1.98% | ||
| Operating Margin | 1.62% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 108,452.04 | 88,602.27 | 101,594.44 | 109,995.42 | 134,909.84 | 149,660 | 176,960 | 7.99% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +195.23 | -4.07 | -51.65 | -97.47 | +1373.41 | +264.35 | +71.57 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hanall Biopharma Co Ltd is a Korea-based company principally engaged in the manufacture and distribution of synthetic pharmaceuticals and biopharmaceuticals. The Company mainly manufactures and sells pharmaceutical products including antidiabetic drugs, skin drugs, muscle relaxants, hepatitis drugs, digestion drugs, anti-cardiovascular drugs, neurologic drugs, interferons, antiviral drugs, antibiotics, antihistamine, anti-inflammatory drugs, and others. The Company also engages in the leasing of real estates. The Company distributes its products in domestic and overseas markets.
Directors
- Seong Wuk Kim CEO (45)
- Seong Jun Choi VPR (48)
- Nam Yong Cho MDR (58)
- Han Su Lee OTH (48)
- Seong Jin Kim OTH (52)
- Seung Guk Park DRC (50)
- Seung Won Yoo NID (47)
- Jong Yin Yook NID (50)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 20th, 1973
- Public Since
- December 18th, 1989
- No. of Shareholders
- 27,255
- No. of Employees
- 408
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 50,693,117
- Address
- 43, Sangseodang 1-gil, Daedeok-gu, DAEJEON, 34344
- Web
- http://www.hanall.co.kr/
- Phone
- +82 429325997
- Auditors
- KPMG Samjong Accounting Corp
Upcoming Events for 009420
Q2 2024 Hanall Biopharma Co Ltd Earnings Release
Similar to 009420
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
What is the Hanall Biopharma Co share price?
As of Today at 19:10 UTC, shares in Hanall Biopharma Co are trading at KR₩32,200. This share price information is delayed by 15 minutes.
How has the Hanall Biopharma Co share price performed this year?
Shares in Hanall Biopharma Co last closed at KR₩32,200 and the price had moved by +51.06% over the past 365 days. In terms of relative price strength the Hanall Biopharma Co share price has outperformed the FTSE Developed Asia Pacific Index by +57.67% over the past year.
What are the analyst and broker recommendations for Hanall Biopharma Co?
The overall consensus recommendation for Hanall Biopharma Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Hanall Biopharma Co dividend yield?
Hanall Biopharma Co does not currently pay a dividend.
Does Hanall Biopharma Co pay a dividend?
Hanall Biopharma Co does not currently pay a dividend.
When does Hanall Biopharma Co next pay dividends?
Hanall Biopharma Co does not currently pay a dividend.
How do I buy Hanall Biopharma Co shares?
To buy shares in Hanall Biopharma Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Hanall Biopharma Co?
As of the previous close price of KR₩32,200, shares in Hanall Biopharma Co had a market capitalisation of KR₩2tn.
Where are Hanall Biopharma Co shares listed?
Here are the trading details for Hanall Biopharma Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 009420
What kind of share is Hanall Biopharma Co?
Based on an overall assessment of its quality, value and momentum Hanall Biopharma Co is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Hanall Biopharma Co share price forecast for 2024?
The analyst consensus target price for shares in Hanall Biopharma Co is KR₩43,000. That is 33.54% above the last closing price of KR₩32,200.
Analysts covering Hanall Biopharma Co currently have a consensus Earnings Per Share (EPS) forecast of KR₩254 for the next financial year.
What is the trend in the Hanall Biopharma Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hanall Biopharma Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -9.16%.
As of the last closing price of KR₩32,200, shares in Hanall Biopharma Co were trading +2.45% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Hanall Biopharma Co PE Ratio?
The Hanall Biopharma Co PE ratio based on its reported earnings over the past 12 months is 104.11. The shares last closed at KR₩32,200.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Hanall Biopharma Co?
Hanall Biopharma Co's management team is headed by:
- Seong Wuk Kim - CEO
- Seong Jun Choi - VPR
- Nam Yong Cho - MDR
- Han Su Lee - OTH
- Seong Jin Kim - OTH
- Seung Guk Park - DRC
- Seung Won Yoo - NID
- Jong Yin Yook - NID